2-Methylene-19-nor-1alpha-hydroxyvitamin D3 analogs inhibit adipocyte differentiation and PPARgamma2 gene transcription

• Published in: Archives of biochemistry and biophysics Vol. 460; no. 2; pp. 192 - 201
• Main Authors: Thomson, Brian, Ahrens, Jamie M, Ntambi, James M, DeLuca, Hector F, Clagett-Dame, Margaret
• Format: Journal Article
• Language: English
• Published: United States 15.04.2007
• Subjects: 3T3 Cells; Active Transport, Cell Nucleus - drug effects; Adipocytes - cytology; Adipocytes - metabolism; Animals; Calcitriol - analogs & derivatives; Calcitriol - pharmacology; Cell Differentiation - drug effects; Cell Nucleus - metabolism; Mice; PPAR gamma - biosynthesis; PPAR gamma - genetics; Transcription, Genetic - drug effects; Vitamins - pharmacology
• ISSN: 0003-9861

The hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), prevents adipogenesis in the 3T3-L1 preadipocyte cell line. In this paper, both a shortened side-chain non-calcemic analog, (20S)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol (2MbisP), as well as a highly bone-selective compound, 2-methylene-19-nor-(20S)-1alpha-hydroxyvitamin D3 (2MD), are shown to completely prevent adipocyte differentiation in this cell line. 2MbisP is slightly less potent than 1,25(OH)2D3, whereas 2MD is approximately two orders of magnitude more potent that the parent hormone in preventing adipocyte differentiation. The ability to block differentiation requires binding to the vitamin D receptor. Both 1,25(OH)2D3 and the analogs prevent the induction of the C/EBPalpha and PPARgamma2 transcription factors, which is necessary for terminal differentiation. In contrast, the normal increase in C/EBPbeta protein that occurs shortly after the induction of differentiation occurs both in the presence and absence of vitamin D compounds, and the C/EBPbeta protein appears functional with respect to DNA binding and nuclear localization. Transient transfection studies show that 1,25(OH)2D3 prevents transactivation through the 5' region of the PPARgamma2 promoter, and thus acts at the transcriptional level to inhibit the normal upregulation of PPARgamma2 that occurs during the course of 3T3-L1 cell differentiation.